Bio Integrates 2024
Anglia Ruskin University, Cambridge, 15 May 2024
Engage with top executives in biotech, CDMO, supply chain, and funding & investment to discuss the major challenges impacting the Biotech sector.
KEYNOTES, FIRESIDE CHATS AND PANEL DISCUSSIONS
PLEASE NOTE The timings have not been finalised so maybe subject to change.
Headline Sponsor:
Gold Sponsors: |
Silver Sponsor: |
|
|
Bronze Sponsors: |
|
|
|
|
|
|
Registration & Networking
08:30 – 09:30
Registration and networking
Welcome & Opening Remarks
09:30 – 09:45
Introduction |
Opening Remarks |
|
|
|
Fireside Chat 1
09:45 – 10:05
Fireside Chat 1 |
|
|
|
Interviewed by:Martino Picardo
|
Fireside Chat 2
10:05 – 10:25
Fireside Chat 2 |
|
|
|
Interviewed by:Martino Picardo
|
ENABLERS
Discussing key factors in the wider biotech ecosystem – other than the science – that underpin success
MAKING IT
On the tools, techniques and strategies to bring biotech innovations to the market
Session 1
10:30 – 11:20
Money in, money out
In a competitive market, how do you stand out to attract investors? How can your IP strategy enable you to gain market share, attract more investments, and create a meaningful ROI?
Facilitated by:
Jenny Laird
VP, Search & Evaluation Neuroscience, Eli Lilly
Panellists Include:
Marc Wilkinson
Partner, UK & European Patent Attorney, Patent Attorney Litigator, J A Kemp
Bradley Hardiman
Senior Director, Ventures – Business Development, Astellas Pharma Europe
Camilla Easter
CEO, Oxford Medical Products
Katharine Robinson
Principal Associate at Mills & Reeve LLP
Alex Brown
Sr. Investment Associate,
Intelligent Artificial Intelligence
AI is very much a buzzword across industries, including the biotech industry. How can we adopt an intelligent AI strategy to maximise benefits and minimise risks?
Facilitated by:
James Fry
Partner and Head of Life Sciences Practice at Mills & Reeve
Panellists include:
Joshua Blight
Co-Founder & CEO, Baseimmune
Dean Plumbley
CTO and Head of AI, CoSyne Therapeutics
Alison Jones
Science Director, Chemistry, Charles River Laboratories
Martin-Immanuel Bittner
Co-Founder & CEO, Arctoris
Sam Windsor
Chief Executive Officer, Ignota Labs
Networking Coffee Break
11:20 – 11:50
Networking Coffee Break
Session 2
11:50 – 12:20
Removing the ‘late’ from ‘regulate’ – the benefits of engaging early
As biotech products become increasingly innovative, it’s essential to engage with regulators. How can engaging with regulators early and often help you overcome hurdles, understand data requirements, and maximise the benefits of innovation?
Facilitated by:
Kathryn Simpson
Director, Kathryn Simpson Consulting Limited
Panellists Include:
CEO, CSO, Vitarka Therapeutics
Suzanne DillyÂ
Chief Executive Officer at VALIRX PLC
Moein Moghimi
Professor of Pharmaceutics and Nanomedicine, Newcastle University
From lab to large-scale
New technologies enable drugs to be manufactured more efficiently, more compliantly, and at a lower cost. What is the role of advanced, automated, data-controlled processes in the future of biopharmaceutical manufacturing?
Panellists include:
Richard Vellacott
Chief Executive Officer, BiologIC Technologies
Amrik Basran
Chief Discovery Officer, Turbine AI
Neil Wetherall
Managing Director, Factorytalk UK
François Hallac
RNA by Design Leader, Centillion Technology
Session 3
12:25 – 13:15
The place to be
The UK has a strong network of biotech hubs, science parks, and innovation hotspots. How do you choose your location to maximise your growth?
Facilitated by:
Bev Vaughan
Arise Innovation Hubs Director, Anglia Ruskin University
Panellists include:
Mayer Schreiber
Chief Executive Officer, Discovery Park
Nuno Alves
Associate Director – Business Development, Astellas Europe
Steven Trim
Director, Venomtech Ltd
Rich Ferrie
Chief Executive Officer, London BioScience Innovation Centre (LBIC)
Kristin Anne Rutter
Executive Director, Cambridge University Health Partners
Networking Lunch
13:15 – 14:15
Networking Lunch
Session 4
14:15 – 15:05
Productive partnerships
When time is money, an efficient partnership can be the key to success. What is the key to a healthy partnership between a biotech and CDMO/CMO, and how do partnerships evolve with the changing needs of a growing biotech?
Facilitated by:
Nathalie Huther
Associate Vice President Business Development (CMC),
Panellists include:
Justin Bryans
Chief Scientific Officer (Discovery), Charles River Laboratories
Kevin Cox
Chairman, VALIRX PLC
Helen Barker
Vice President, Global Tech Ops & CMC, Reneo Pharmaceuticals
Kwok Pang
Chief Digital Officer, Adthera Bio
Neil Jones
Chief Commercial Officer, Aenova Group
Session 5
15:10 – 16:00
The workforce of the future
What should the biotech workforce of the future look like? How can we develop new skills and embrace diverse ways of thinking to build a better biotech sector?
Facilitated by:
Panellists include:
Claire Pike
Pro Vice-Chancellor (Education Enhancement) and Professor, Anglia Ruskin University
Shadi Farhangrazi
Chief Executive Officer, S.M. Discovery Group (SMDG)
Lydia Mapstone
CEO and Co-founder at BoobyBiome
Philip Probert
Biologics Technology Lead, CPI
Networking Drinks
16:00 – 17:00
Drinks Reception
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.
Bio Integrates 2024
Anglia Ruskin University, Cambridge, 15 May 2024
Engage with top executives in biotech, CDMO, supply chain, and funding & investment to discuss the major challenges impacting the Biotech sector.
KEYNOTES, FIRESIDE CHATS AND PANEL DISCUSSIONS
PLEASE NOTE The timings have not been finalised so maybe subject to change.
Headline Sponsor:
Gold Sponsors: |
Silver Sponsor: |
|
|
Bronze Sponsors: |
|
|
|
|
|
|
ENABLERS
Discussing key factors in the wider biotech ecosystem – other than the science – that underpin success
MAKING IT
On the tools, techniques and strategies to bring biotech innovations to the market
Registration & Networking
08:30 – 09:30
Welcome & Opening Remarks
09:30 – 09:45
Fireside Chat 1
09:45 – 10:05
Fireside Chat 2
10:05 – 10:25
10:30 – 11:20
Session 1
Track one:
Money in, money out
In a competitive market, how do you stand out to attract investors? How can your IP strategy enable you to gain market share, attract more investments, and create a meaningful ROI?
Facilitated by:
Jenny Laird
VP, Search & Evaluation Neuroscience, Eli Lilly
Panellists Include:
Marc Wilkinson
Partner, UK & European Patent Attorney, Patent Attorney Litigator, J A Kemp
Bradley Hardiman
Senior Director, Ventures – Business Development, Astellas Pharma Europe
Camilla Easter
CEO, Oxford Medical Products
Katharine Robinson
Principal Associate at Mills & Reeve LLP
Alex Brown
Sr. Investment Associate,
Track two:
Intelligent Artificial Intelligence
AI is very much a buzzword across industries, including the biotech industry. How can we adopt an intelligent AI strategy to maximise benefits and minimise risks?
Facilitated by:
James Fry
Partner and Head of Life Sciences Practice at Mills & Reeve
Panellists include:
Joshua Blight
Co-Founder & CEO, Baseimmune
Dean Plumbley
CTO and Head of AI, CoSyne Therapeutics
Alison Jones
Science Director, Chemistry, Charles River Laboratories
Martin-Immanuel Bittner
Co-Founder & CEO, Arctoris
Sam Windsor
Chief Executive Officer, Ignota Labs
Networking Coffee
11:20 – 11:50
11:50 – 12:20
Session 2
Track one:
Removing the ‘late’ from ‘regulate’ – the benefits of engaging early
As biotech products become increasingly innovative, it’s essential to engage with regulators. How can engaging with regulators early and often help you overcome hurdles, understand data requirements, and maximise the benefits of innovation?
Facilitated by:
Kathryn Simpson
Director, Kathryn Simpson Consulting Limited
Panellists Include:
CEO, CSO, Vitarka Therapeutics
Suzanne DillyÂ
Chief Executive Officer at VALIRX PLC
Moein Moghimi
Professor of Pharmaceutics and Nanomedicine, Newcastle University
Track two:
From lab to large-scale
New technologies enable drugs to be manufactured more efficiently, more compliantly, and at a lower cost. What is the role of advanced, automated, data-controlled processes in the future of biopharmaceutical manufacturing?
Panellists include:
Richard Vellacott
Chief Executive Officer, BiologIC Technologies
Amrik Basran
Chief Discovery Officer, Turbine AI
Neil Wetherall
Managing Director, Factorytalk UK
François Hallac
RNA by Design Leader, Centillion Technology
12:25 – 13:15
Session 3:
The place to be
The UK has a strong network of biotech hubs, science parks, and innovation hotspots. How do you choose your location to maximise your growth?
Facilitated by:
Bev Vaughan
Arise Innovation Hubs Director, Anglia Ruskin University
Panellists include:
Mayer Schreiber
Chief Executive Officer, Discovery Park
Nuno Alves
Associate Director – Business Development, Astellas Europe
Steven Trim
Director, Venomtech Ltd
Rich Ferrie
Chief Executive Officer, London BioScience Innovation Centre (LBIC)
Kristin Anne Rutter
Executive Director, Cambridge University Health Partners
Networking Lunch
13:15 – 14:15
14:15 – 15:05
Session 4:
Productive partnerships
When time is money, an efficient partnership can be the key to success. What is the key to a healthy partnership between a biotech and CDMO/CMO, and how do partnerships evolve with the changing needs of a growing biotech?
Facilitated by:
Nathalie Huther
Associate Vice President Business Development (CMC),
Panellists include:
Justin Bryans
Chief Scientific Officer (Discovery), Charles River Laboratories
Kevin Cox
Chairman, VALIRX PLC
Helen Barker
Vice President, Global Tech Ops & CMC, Reneo Pharmaceuticals
Kwok Pang
Chief Digital Officer, Adthera Bio
Neil Jones
Chief Commercial Officer, Aenova Group
15:10 – 16:00
Session 5:
The workforce of the future
What should the biotech workforce of the future look like? How can we develop new skills and embrace diverse ways of thinking to build a better biotech sector?
Facilitated by:
Panellists include:
Claire Pike
Pro Vice-Chancellor (Education Enhancement) and Professor, Anglia Ruskin University
Shadi Farhangrazi
Chief Executive Officer, S.M. Discovery Group (SMDG)
Lydia Mapstone
CEO and Co-founder at BoobyBiome
Philip Probert
Biologics Technology Lead, CPI
Networking Drinks Reception
16:00 – 17:00
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.